A study of efficacy of humanized anti-human IgE monoclonal antibody, omalizumab for the treatment of severe nonatopic asthma
Phase 2
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-UMIN000005723
- Lead Sponsor
- Hamamatsu Rosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with active cardiopulmonary diseases other than bronchial asthma or serious medical conditions (e.g. malignancy)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the number of unscheduled hospital visit and systemic corticosteroid rescue for exacerbation of asthma during in 6-month observation and 6-month treatment period
- Secondary Outcome Measures
Name Time Method Change in Asthma Control Test(ACT) score, forced expiratory volume in 1 second, fractional exhaled nitric oxide concentration before and after omalizumab treatment